tbuckley/cabot-search huggingface dataset:
Shall The Journal be Removed to Washington?
Authors: Henry T. Godfrey
Journal: JAMA (1891)

<h3>To the Editor:</h3> —If the home ofThe Journalmust be removed from Chicago, let it come to Galena, Ill. It was the home of Grant, Washburn, Rawlins and other great men. It is far more central than Washington and has eight physicians, equally inexperienced in editorial work with their brethren of the Capital City, and equally full of enthusiasm for the good work. We of Galena are far from the maddening and demoralizing influence of political parties and their intrigues, and when we come home from our muddy country rides and hang up our splashed overcoats, we can give to our editorial work the full power of our massive intellects. I think Chicago the proper place for the home ofThe Journal, but as I said before, if it must be removed let it come to the central city of Galena, and not to the outer edge of the
In-Training Examination in Internal Medicine
Authors: Norman A. Desbiens
Journal: Annals of Internal Medicine (1995)

Letters1 January 1995In-Training Examination in Internal MedicineNorman A. Desbiens, MDNorman A. Desbiens, MDMarshfield Clinic; Marshfield, WI 54449Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-1-199501010-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I thank Garibaldi and colleagues [1] for their recent description of the results of the ITE-IM for the last 6 years. Our residents have participated in this program since its inception, and I have found it to be a valuable feedback and heuristic tool.The authors point out a trend toward lower total scores for all cohorts. They postulate that this finding might reflect either an increased level of difficulty in the examination or a decreased level of knowledge among examinees, but selection bias[2] may also explain part or all of this finding. For example, because the ...References1. Garibaldi RA, Trontell MC, Waxman H, Holbrook JH, Kanya DT, Khoshbin S, et al. The In-Training Examination in Internal Medicine. Ann Intern Med. 1994; 121:117-23. Google Scholar2. Kleinbaum DG, Kupper LL, Morgenstern H. Selection bias. In: Beal C, ed. Epidemiologic Research. New York: Van Nostrand Reinhold; 1982:194-219. Google Scholar Author, Article, and Disclosure InformationAffiliations: Marshfield Clinic; Marshfield, WI 54449 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1995Volume 122, Issue 1Page: 73-74 Issue Published: 1 January 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Authors: Joseph McEvoy
Journal: American Journal of Psychiatry (2007)

Objective: This 52-week randomized, double-blind, flexible-dose, multicenter study evaluated the overall effectiveness (as measured by treatment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients early in the course of psychotic illness. Method: Patients were randomly assigned to treatment with olanzapine (2.5–20 mg/day), quetiapine (100–800 mg/day), or risperidone (0.5–4 mg/day) administered in twice-daily doses. Statistical analyses tested for noninferiority in all-cause treatment discontinuation rates up to 52 weeks (primary outcome measure) based on a prespecified noninferiority margin of 20%. Results: A total of 400 patients were randomly assigned to treatment with olanzapine (N=133), quetiapine (N=134), or risperidone (N=133). The mean modal prescribed daily doses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risperidone. At week 52, all-cause treatment discontinuation rates were 68.4%, 70.9%, and 71.4% for olanzapine, quetiapine, and risperidone, respectively. Reductions in total score on the Positive and Negative Syndrome Scale (PANSS) were similar for the three treatment groups, but reductions in PANSS positive subscale scores were greater in the olanzapine group (at 12 weeks and at 52 weeks or withdrawal from study) and the risperidone group (at 12 weeks). The most common elicited adverse events for olanzapine were drowsiness (53%), weight gain (51%), and insomnia (38%); for quetiapine, drowsiness (58%), increased sleep hours (42%), and weight gain (40%); and for risperidone, drowsiness (50%), menstrual irregularities in women (47%), and weight gain (41%). Conclusions: Olanzapine, quetiapine, and risperidone demonstrated comparable effectiveness in early-psychosis patients, as indicated by similar rates of all-cause treatment discontinuation.
Cost-Effectiveness of Implantable Defibrillators versus the Drug Amiodarone To Prevent Abnormal Heart Rhythms after Heart Attack
Journal: Annals of Internal Medicine (2001)

Summaries for Patients20 November 2001Cost-Effectiveness of Implantable Defibrillators versus the Drug Amiodarone To Prevent Abnormal Heart Rhythms after Heart AttackSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-10-200111200-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?After a heart attack, some patients develop a dangerous heart rhythm called sustained ventricular arrhythmia. If the patient is in the hospital, doctors or nurses apply an electric shock to the chest to stop the rhythm (external cardioversion). It is now possible to place a device called an implantable cardioverter defibrillator (ICD), which monitors heart rhythm, inside the chest. When it detects a dangerous rhythm, it applies an electrical shock to restore a normal heart rhythm. The ICD improves the survival of people who have had sustained ventricular ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction.” It is in the 20 November 2001 issue of Annals of Internal Medicine (volume 135, pages 870–883). The authors are GD Sanders, MA Hlatky, NR Every, KM McDonald, PA Heidenreich, LS Parsons, and DK Owens.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPotential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction Gillian D. Sanders , Mark A. Hlatky , Nathan R. Every , Kathryn M. McDonald , Paul A. Heidenreich , Lori S. Parsons , and Douglas K. Owens Metrics 20 November 2001Volume 135, Issue 10Page: I-56KeywordsArrhythmiaDrugsHeartHeart failureImplantable cardioverter defibrillatorsMyocardial infarctionQuality adjusted life yearsShockSimulation and modelingThorax ePublished: 20 November 2001 Issue Published: 20 November 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial
Authors: Brian Lian, Rohit Loomba, Joel Neutel, Carmen Margaritescu, Ken Homer, Amy Luk, Marianne Mancini, Summer Ji, Geoff Barker, Randall Severance, Rizwana Mohseni, David Bernard, Michael Dao
Journal: Journal of Hepatology (2020)
Nucleotide variability in the 5?noncoding (5?NC) region of HCV subtype 1b and response to inerferon . Div. Med. Interna, Osp. Cervello; Ist. Med. Generale, Div. Biol. Cellulare and Ist. Statistica, University of Palermo, Italy; Innogenetics, Belgium; Chiron Co. USA
Journal: Hepatology (1995)
THE NECESSITY FOR TRAINED AND EDUCATED HEALTH OFFICIALS.
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Without Conscience
Authors: Elie Wiesel
Journal: New England Journal of Medicine (2005)

Interview with Professor Elie Wiesel on physicians and the Holocaust. (12:34)Download This is one of those stories that invite fear.Now we know. During the period of the past century that I call Night, medicine was practiced in certain places not to heal but to harm, not to fight off death but to serve it.(Figure)In the conflict between Good and Evil during the Second World War, the infamous Nazi doctors played a crucial role. They preceded the torturers and assassins in the science of organized cruelty that we call the Holocaust. There is a Talmudic adage, quite disturbing, that applies to them: Tov she-barofim le-gehinom — “The best . . .
Audiovisual Materials Available From the American Cancer Society
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Audiovisual Materials Available From the American Cancer Society Get access JNCI: Journal of the National Cancer Institute, Volume 53, Issue 2, August 1974, Page 598, https://doi.org/10.1093/jnci/53.2.598-a Published: 01 August 1974
Increase in Rubella and Congenital Rubella
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Continuum of Care Lacking for Blacks With HIV Infection
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PAI-1 in diabetic nephropathy
Authors: Alexandre Hertig, Gaelle Pelle, Eric Rondeau
Journal: Kidney International (2005)

To the Editor: The mechanisms by which plasminogen activator inhibitor-1 (PAI-1), the main plasminogen activator inhibitor, promotes fibrosis in a number of experimental models, are still intensely debated. On the one hand, PAI-1 is supposed to inhibit extracellular matrix degradation by preventing plasmin formation. On the other hand, it has been shown to prevent transforming growth factor (TGF) beta activation and, thus, to prevent extracellular matrix production1.Hertig A. Rondeau E. Plasminogen activator inhibitor type 1: The two faces of the same coin.Curr Opin Nephrol Hypertens. 2004; 13: 39-44Google Scholar. Nicholas et al recently provided experimental, in vivo data suggesting that PAI-1 deficiency might be helpful in the prevention of diabetic nephropathy: when compared to wild-type animals, PAI-1 knockout mice have, thus, a lower urinary albumin excretion and a lower synthesis of fibronectin in the kidney after streptozotocin injection2.Nicholas S.B. Aguiniga E. Ren Y. et al.Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.Kidney Int. 2005; 67: 1297-1307Google Scholar. Interestingly, PAI-1 is reported by these authors to enhance TGF beta synthesis by mesangial cells, a finding that is somewhat provocative because TGF beta is itself a potent enhancer of the PAI-1 promoter gene, and because recent works by Luttun et al and our group demonstrated that PAI-1 plays a critical role in the regulation of the TGF beta activation (i.e., PAI-1 inhibits TGF-beta activation)3.Luttun A. Lupu F. Storkebaum E. et al.Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.Arterioscler Thromb Vasc Biol. 2002; 22: 499-505Google Scholar , 4.Hertig A. Berrou J. Allory Y. et al.Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.FASEB J. 2003; 17: 1904-1906Google Scholar. Moreover, in Nicholas' study, the induction of TGF-beta synthesis, at the mRNA and at the protein level, in diabetic PAI-1 +/+ mice, is weak when compared with nondiabetic mice (×1.5), and is hardly distinguishable from the induction observed in PAI-1 -/- mice, at least for the eye Figure 3. Another striking result is that the level of TGF-beta expression and production by the kidney is higher in PAI-1 -/- mice than in PAI-1 +/+ mice, in either basal or diabetic conditions. In the absence of pathologic data, including measurements of the glomerular basement membrane thickness, it is therefore difficult to conclude that PAI-1 knockout animals could be protected towards diabetic nephropathy and that this would be related to a lower concentration of TGF-beta.
Hazardous Solid Waste from Agriculture
Authors: Raymond C. Loehr
Journal: Environmental Health Perspectives (1978)

Large quantities of food processing, crop, forestry, and animal solid wastes are generated in the United States each year. The major components of these wastes are biodegradable. However, they also contain components such as nitrogen, human and animal pathogens, medicinals, feed additives, salts, and certain metals, that under uncontrolled conditions can be detrimental to aquatic, plant, animal, or human life. The most common method of disposal of these wastes is application to the land. Thus the major pathways for transmission of hazards are from and through the soil. Use of these wastes as animal feed also can be a pathway. While at this time there are no crises associated with hazardous materials in agricultural solid wastes, the potential for problems should not be underestimated. Manpower and financial support should be provided to obtain more detailed information in this area, esepcially to better delineate transport and dispersal and to determine and evaluate risks.
Erratum
Authors: Robyn M. Dawes
Journal: Behavioral and Brain Sciences (1989)

In my comments in BBS (Random generators, ganzfields, analysis, and theory, 1987, 10:581-82) regarding psi, I mistakenly ascribed to Professor Honorton the position that "good experimenters knew in advance that the assertion in the paper I cited (1985), and in fact regards it as a rather foolish one (personal communication 6/25/88). This incorrect assertion was based on my inference - not his - that the most plausible alternative to optional stopping for the negative correlation between sample size and effect size (and even z-scores) was prior knowledge leading to the necessity of sampling fewer observations when the expectation of the estimated effect size was larger. Honorton, C. (1985) The Ganzfeld psi experiment: A critical appraisal. Journal of Parapsychology 49:51-91.
Establishment of VARIVAX® Pregnancy Registry
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Air pollution in New Guinea. Cause of chronic pulmonary disease among stone-age natives in the Highlands
Authors: K. M. Master
Journal: JAMA (1974)

Inhabitants of villages in the Highlands of New Guinea wear scant clothing. To keep warm during cold nights they burn smoky fires in small closed huts, where they inhale extremely high levels of particulate matter and aldehydes. Pulmonary disease, mainly obstructive but also restrictive, appears at an early age and was present in 78% of subjects over age 40 years. Severely affected subjects have diminished breath sounds, coarse rales, and decreased chest cage movement. Pathologic specimens from affected subjects demonstrated centrilobular emphysema, thickened pleura, pulmonary fibrosis, mucous gland hypertrophy, and deposition of anthracotic pigment. Other factors probably responsible for the high prevalence of pulmonary disease include smoking of home grown tobacco, protein malnutrition, poor sanitation, and various endemic diseases. (<i>JAMA</i>228:1653-1655, 1974)
Abstract 3813: PHB2 inactivation by AKAP-BIG3 is required for progression of HER2-overexpressing breast cancer
Authors: Tetsuro Yoshimaru, Yosuke Matsushita, Mitsunori Sasa, Yasuo Miyoshi, Toyomasa Katagiri
Journal: Cancer Research (2019)

Abstract Overexpression of the human epidermal growth factor receptor 2 (HER2) in breast cancer is linked to aggressive tumor behavior and a poorer prognosis. Anti-HER2 monoclonal antibody, trastuzumab extends the overall survival of patients with HER2-overexpressing breast cancer, but resistance to trastuzumab and/or other HER2-targeted therapies remains a serious clinical problem. Our previous studies demonstrated that Brefeldin A-Inhibited Guanine nucleotide-exchange protein 3 (BIG3), which is exclusively overexpressed in the majority of breast cancers, functions as a cancer specific A-kinase anchoring protein that binds protein kinase A (PKA) and protein phosphatase 1 (PP1Cα), thereby inactivating prohibitin2 (PHB2) suppressive activity through its dephosphorylation on Ser39. We further developed dominant-negative stapling peptide (stERAP), which is designed to specifically disrupt binding of BIG3-PHB2 complex and improve duration of their anti-tumor effects. Here we newly report that stERAP has significant suppressive effects on the HER2 signaling network by activating the tumor suppressive ability of PHB2. stERAP resulted in intrinsic PHB2 release from BIG3, followed by rapid phosphorylation on Ser39, Thr42 and Thr169 via PKCα, TTK and MK5, respectively. Importantly, PHB2 released from BIG3 by stERAP treatment translocated into nucleus, followed by acting as a transcriptional co-repressor by recruiting HDAC1 and NcoR through its Ser39-phosphorylation. More importantly, we observed that serine/threonine phosphorylations of PHB2 are necessary for disruption of HER2-HER3 hetero-dimerization and NF-κB signalling activation which are associated with acquired resistance to trastuzumab. We demonstrated that weekly treatment of stERAP completely suppressed the proliferation of trastuzumab-resistant HER2-positive breast cancer cells in vitro and in vivo. We are currently examining the association of both BIG3 overexpression and PHB2 dephosphorylation with poor prognosis of patients with HER2-positive breast cancers by immunohistochemical staining, and will report these results at this meeting. We demonstrated for the first time that PHB2 inactivation by the AKAP-BIG3 (BIG3/PKA/PP1Cα tri-complex) is required for oncogenic HER2 signalling activation in breast cancer cells, and stERAP may be a promising anti-cancer drug for trastuzumab-resistant breast cancer. Citation Format: Tetsuro Yoshimaru, Yosuke Matsushita, Mitsunori Sasa, Yasuo Miyoshi, Toyomasa Katagiri. PHB2 inactivation by AKAP-BIG3 is required for progression of HER2-overexpressing breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3813.